Update (4:52 p.m.): Updated with Thursday market close information.
NEW YORK (TheStreet) -- Merrimack Pharmaceuticals (MACK - Get Report) soared more than 60% to a one-year high of $7.65 on Thursday after the company announced its experimental cancer treatment MM-398 showed improved results in a late-stage study.
The company announced the treatment improved the overall survival rate in patients with metastatic pancreatic cancer when used in combination with two other drugs in the study. Merrimack said the drug combination yielded an overall survival rate of 6.1 months, compared to 4.2 months yielded by the other two drugs in patients who had previously received the chemotherapy drug gemcitabine.
The stock closed up 59.23%, or $2.60, to $6.99. Nearly 30 million shares changed hands, which eclipsed the average volume of 1,352,450. The stock hit a low of $6.55 for the day and holds a 52-week low of $2.05.Must Read: Warren Buffett's 10 Favorite Growth Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts